+443.7%
APLD vs MRNA
-8.1%
+451.8%
-81.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.8% | -2.2% | +4.0% | +2.0% |
| 7D | +4.1% | +5.5% | -1.4% | +3.3% |
| 30D | -11.7% | +158.7% | -170.4% | -31.4% |
| 3M | -40.3% | +182.1% | -222.4% | -55.5% |
| 6M | -8.0% | +151.8% | -159.8% | -29.1% |
| YTD | +7.5% | +393.6% | -386.0% | -35.7% |
| 1Y | +84.0% | +499.5% | -415.4% | +1.5% |
| 3Y | +356.2% | +29.3% | +326.9% | +293.1% |
| All | +443.7% | -8.1% | +451.8% | +333.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling